nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Dactinomycin—sarcoma	0.0406	0.289	CbGbCtD
Carfilzomib—ABCB1—Mitoxantrone—sarcoma	0.0363	0.259	CbGbCtD
Carfilzomib—ABCB1—Vincristine—sarcoma	0.025	0.178	CbGbCtD
Carfilzomib—ABCB1—Etoposide—sarcoma	0.0229	0.163	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—sarcoma	0.0156	0.111	CbGbCtD
Carfilzomib—PSMB10—hematopoietic system—sarcoma	0.00969	0.0429	CbGeAlD
Carfilzomib—PSMB2—mammary gland—sarcoma	0.00772	0.0342	CbGeAlD
Carfilzomib—PSMB8—myometrium—sarcoma	0.00727	0.0322	CbGeAlD
Carfilzomib—PSMB10—lymphoid tissue—sarcoma	0.00682	0.0302	CbGeAlD
Carfilzomib—PSMB8—seminal vesicle—sarcoma	0.00657	0.0291	CbGeAlD
Carfilzomib—PSMB5—myometrium—sarcoma	0.00642	0.0284	CbGeAlD
Carfilzomib—PSMB5—seminal vesicle—sarcoma	0.0058	0.0257	CbGeAlD
Carfilzomib—PSMB10—Vinblastine—Vincristine—sarcoma	0.00576	0.474	CbGdCrCtD
Carfilzomib—PSMB1—myometrium—sarcoma	0.00561	0.0249	CbGeAlD
Carfilzomib—PSMB2—myometrium—sarcoma	0.00548	0.0243	CbGeAlD
Carfilzomib—PSMB1—embryo—sarcoma	0.0054	0.0239	CbGeAlD
Carfilzomib—PSMB10—testis—sarcoma	0.00531	0.0235	CbGeAlD
Carfilzomib—PSMB2—embryo—sarcoma	0.00527	0.0233	CbGeAlD
Carfilzomib—PSMB1—seminal vesicle—sarcoma	0.00507	0.0225	CbGeAlD
Carfilzomib—PSMB10—liver—sarcoma	0.00502	0.0222	CbGeAlD
Carfilzomib—PSMB2—seminal vesicle—sarcoma	0.00495	0.0219	CbGeAlD
Carfilzomib—PSMB5—smooth muscle tissue—sarcoma	0.00486	0.0215	CbGeAlD
Carfilzomib—PSMB1—hematopoietic system—sarcoma	0.00482	0.0213	CbGeAlD
Carfilzomib—PSMB2—hematopoietic system—sarcoma	0.0047	0.0208	CbGeAlD
Carfilzomib—PSMB2—connective tissue—sarcoma	0.00453	0.0201	CbGeAlD
Carfilzomib—PSMB1—smooth muscle tissue—sarcoma	0.00425	0.0188	CbGeAlD
Carfilzomib—PSMB1—skin of body—sarcoma	0.00419	0.0186	CbGeAlD
Carfilzomib—PSMB5—cardiac atrium—sarcoma	0.00419	0.0185	CbGeAlD
Carfilzomib—PSMB5—uterus—sarcoma	0.00417	0.0184	CbGeAlD
Carfilzomib—PSMB2—smooth muscle tissue—sarcoma	0.00414	0.0183	CbGeAlD
Carfilzomib—PSMB8—tendon—sarcoma	0.00413	0.0183	CbGeAlD
Carfilzomib—PSMB2—skin of body—sarcoma	0.00409	0.0181	CbGeAlD
Carfilzomib—PSMB8—bone marrow—sarcoma	0.004	0.0177	CbGeAlD
Carfilzomib—PSMB10—lymph node—sarcoma	0.00385	0.017	CbGeAlD
Carfilzomib—PSMB1—cardiac atrium—sarcoma	0.00366	0.0162	CbGeAlD
Carfilzomib—PSMB5—tendon—sarcoma	0.00365	0.0162	CbGeAlD
Carfilzomib—PSMB1—uterus—sarcoma	0.00364	0.0161	CbGeAlD
Carfilzomib—PSMB2—cardiac atrium—sarcoma	0.00357	0.0158	CbGeAlD
Carfilzomib—PSMB2—uterus—sarcoma	0.00355	0.0157	CbGeAlD
Carfilzomib—PSMB5—bone marrow—sarcoma	0.00354	0.0157	CbGeAlD
Carfilzomib—PSMB8—testis—sarcoma	0.00342	0.0151	CbGeAlD
Carfilzomib—PSMB1—lymphoid tissue—sarcoma	0.00339	0.015	CbGeAlD
Carfilzomib—PSMB2—lymphoid tissue—sarcoma	0.00331	0.0147	CbGeAlD
Carfilzomib—PSMB8—liver—sarcoma	0.00323	0.0143	CbGeAlD
Carfilzomib—PSMB8—Vinorelbine—Vincristine—sarcoma	0.0032	0.263	CbGdCrCtD
Carfilzomib—PSMB8—Podofilox—Etoposide—sarcoma	0.00319	0.263	CbGdCrCtD
Carfilzomib—PSMB1—tendon—sarcoma	0.00319	0.0141	CbGeAlD
Carfilzomib—PSMB2—tendon—sarcoma	0.00311	0.0138	CbGeAlD
Carfilzomib—PSMB1—bone marrow—sarcoma	0.00309	0.0137	CbGeAlD
Carfilzomib—PSMB5—testis—sarcoma	0.00302	0.0134	CbGeAlD
Carfilzomib—PSMB2—bone marrow—sarcoma	0.00301	0.0133	CbGeAlD
Carfilzomib—Myocardial ischaemia—Mitoxantrone—sarcoma	0.00286	0.00924	CcSEcCtD
Carfilzomib—PSMB5—liver—sarcoma	0.00286	0.0127	CbGeAlD
Carfilzomib—Musculoskeletal chest pain—Epirubicin—sarcoma	0.00277	0.00893	CcSEcCtD
Carfilzomib—PSMB1—testis—sarcoma	0.00264	0.0117	CbGeAlD
Carfilzomib—PSMB2—testis—sarcoma	0.00258	0.0114	CbGeAlD
Carfilzomib—Musculoskeletal chest pain—Doxorubicin—sarcoma	0.00256	0.00826	CcSEcCtD
Carfilzomib—PSMB1—liver—sarcoma	0.0025	0.0111	CbGeAlD
Carfilzomib—PSMB8—lymph node—sarcoma	0.00248	0.011	CbGeAlD
Carfilzomib—PSMB2—liver—sarcoma	0.00244	0.0108	CbGeAlD
Carfilzomib—Sepsis—Thiotepa—sarcoma	0.00231	0.00746	CcSEcCtD
Carfilzomib—Sepsis—Dactinomycin—sarcoma	0.0023	0.00741	CcSEcCtD
Carfilzomib—PSMB5—lymph node—sarcoma	0.00219	0.0097	CbGeAlD
Carfilzomib—Hepatic failure—Thiotepa—sarcoma	0.00215	0.00695	CcSEcCtD
Carfilzomib—Hepatic failure—Dactinomycin—sarcoma	0.00214	0.00689	CcSEcCtD
Carfilzomib—Lymphopenia—Epirubicin—sarcoma	0.0021	0.00677	CcSEcCtD
Carfilzomib—Sepsis—Mitoxantrone—sarcoma	0.002	0.00644	CcSEcCtD
Carfilzomib—Lymphopenia—Doxorubicin—sarcoma	0.00194	0.00626	CcSEcCtD
Carfilzomib—PSMB1—lymph node—sarcoma	0.00191	0.00848	CbGeAlD
Carfilzomib—Hepatic failure—Vincristine—sarcoma	0.00191	0.00616	CcSEcCtD
Carfilzomib—PSMB2—lymph node—sarcoma	0.00187	0.00827	CbGeAlD
Carfilzomib—Hypophosphataemia—Epirubicin—sarcoma	0.00185	0.00596	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Mitoxantrone—sarcoma	0.00184	0.00594	CcSEcCtD
Carfilzomib—Cardiac arrest—Thiotepa—sarcoma	0.00184	0.00594	CcSEcCtD
Carfilzomib—Blood creatinine increased—Thiotepa—sarcoma	0.00181	0.00585	CcSEcCtD
Carfilzomib—Renal failure acute—Mitoxantrone—sarcoma	0.00181	0.00584	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Thiotepa—sarcoma	0.00174	0.00562	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Dactinomycin—sarcoma	0.00173	0.00558	CcSEcCtD
Carfilzomib—Hyponatraemia—Vincristine—sarcoma	0.00172	0.00556	CcSEcCtD
Carfilzomib—Pain in extremity—Vincristine—sarcoma	0.00172	0.00554	CcSEcCtD
Carfilzomib—Hypophosphataemia—Doxorubicin—sarcoma	0.00171	0.00551	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Epirubicin—sarcoma	0.00169	0.00545	CcSEcCtD
Carfilzomib—Hyponatraemia—Mitoxantrone—sarcoma	0.00168	0.00541	CcSEcCtD
Carfilzomib—Sepsis—Etoposide—sarcoma	0.00166	0.00536	CcSEcCtD
Carfilzomib—Cardiac arrest—Vincristine—sarcoma	0.00163	0.00526	CcSEcCtD
Carfilzomib—Blood creatinine increased—Mitoxantrone—sarcoma	0.00156	0.00505	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Doxorubicin—sarcoma	0.00156	0.00504	CcSEcCtD
Carfilzomib—Neutropenia—Dactinomycin—sarcoma	0.00155	0.00501	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Vincristine—sarcoma	0.00154	0.00498	CcSEcCtD
Carfilzomib—Hypercalcaemia—Epirubicin—sarcoma	0.00154	0.00498	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Etoposide—sarcoma	0.00153	0.00494	CcSEcCtD
Carfilzomib—Hypokalaemia—Mitoxantrone—sarcoma	0.00152	0.00491	CcSEcCtD
Carfilzomib—Hyperglycaemia—Thiotepa—sarcoma	0.00151	0.00487	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Mitoxantrone—sarcoma	0.0015	0.00485	CcSEcCtD
Carfilzomib—Pneumonia—Thiotepa—sarcoma	0.0015	0.00484	CcSEcCtD
Carfilzomib—Pneumonia—Dactinomycin—sarcoma	0.00149	0.0048	CcSEcCtD
Carfilzomib—Renal failure—Thiotepa—sarcoma	0.00147	0.00473	CcSEcCtD
Carfilzomib—Neuritis—Epirubicin—sarcoma	0.00144	0.00464	CcSEcCtD
Carfilzomib—Hypercalcaemia—Doxorubicin—sarcoma	0.00143	0.00461	CcSEcCtD
Carfilzomib—Neutropenia—Vincristine—sarcoma	0.00139	0.00447	CcSEcCtD
Carfilzomib—Neutropenia—Mitoxantrone—sarcoma	0.00135	0.00436	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Mitoxantrone—sarcoma	0.00134	0.00433	CcSEcCtD
Carfilzomib—Neuritis—Doxorubicin—sarcoma	0.00133	0.00429	CcSEcCtD
Carfilzomib—Pneumonia—Vincristine—sarcoma	0.00133	0.00429	CcSEcCtD
Carfilzomib—Cardiac arrest—Etoposide—sarcoma	0.00132	0.00426	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Vincristine—sarcoma	0.0013	0.00421	CcSEcCtD
Carfilzomib—Hyperglycaemia—Mitoxantrone—sarcoma	0.0013	0.0042	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Vincristine—sarcoma	0.0013	0.00418	CcSEcCtD
Carfilzomib—Pneumonia—Mitoxantrone—sarcoma	0.00129	0.00418	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Mitoxantrone—sarcoma	0.00127	0.0041	CcSEcCtD
Carfilzomib—Renal failure—Mitoxantrone—sarcoma	0.00127	0.00408	CcSEcCtD
Carfilzomib—Cardiac disorder—Thiotepa—sarcoma	0.00124	0.00401	CcSEcCtD
Carfilzomib—Chills—Thiotepa—sarcoma	0.0012	0.00387	CcSEcCtD
Carfilzomib—Chills—Dactinomycin—sarcoma	0.00119	0.00385	CcSEcCtD
Carfilzomib—Hypoaesthesia—Vincristine—sarcoma	0.00118	0.00381	CcSEcCtD
Carfilzomib—Back pain—Thiotepa—sarcoma	0.00113	0.00364	CcSEcCtD
Carfilzomib—Neutropenia—Etoposide—sarcoma	0.00112	0.00362	CcSEcCtD
Carfilzomib—Cardiac disorder—Vincristine—sarcoma	0.0011	0.00355	CcSEcCtD
Carfilzomib—Pneumonia—Etoposide—sarcoma	0.00108	0.00348	CcSEcCtD
Carfilzomib—Anaemia—Thiotepa—sarcoma	0.00108	0.00347	CcSEcCtD
Carfilzomib—Anaemia—Dactinomycin—sarcoma	0.00107	0.00345	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Etoposide—sarcoma	0.00106	0.00341	CcSEcCtD
Carfilzomib—Renal failure—Etoposide—sarcoma	0.00105	0.0034	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Etoposide—sarcoma	0.00105	0.00339	CcSEcCtD
Carfilzomib—Leukopenia—Thiotepa—sarcoma	0.00104	0.00337	CcSEcCtD
Carfilzomib—Chills—Mitoxantrone—sarcoma	0.00104	0.00335	CcSEcCtD
Carfilzomib—Leukopenia—Dactinomycin—sarcoma	0.00103	0.00334	CcSEcCtD
Carfilzomib—Cough—Thiotepa—sarcoma	0.00102	0.00328	CcSEcCtD
Carfilzomib—Hypertension—Thiotepa—sarcoma	0.00101	0.00325	CcSEcCtD
Carfilzomib—Back pain—Vincristine—sarcoma	0.000999	0.00322	CcSEcCtD
Carfilzomib—Arthralgia—Thiotepa—sarcoma	0.000992	0.0032	CcSEcCtD
Carfilzomib—Back pain—Mitoxantrone—sarcoma	0.000973	0.00314	CcSEcCtD
Carfilzomib—Hypoaesthesia—Etoposide—sarcoma	0.000956	0.00309	CcSEcCtD
Carfilzomib—Anaemia—Vincristine—sarcoma	0.000955	0.00308	CcSEcCtD
Carfilzomib—Infection—Thiotepa—sarcoma	0.000945	0.00305	CcSEcCtD
Carfilzomib—Infection—Dactinomycin—sarcoma	0.000937	0.00303	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—sarcoma	0.000931	0.003	CcSEcCtD
Carfilzomib—Thrombocytopenia—Thiotepa—sarcoma	0.000931	0.003	CcSEcCtD
Carfilzomib—Anaemia—Mitoxantrone—sarcoma	0.00093	0.003	CcSEcCtD
Carfilzomib—Leukopenia—Vincristine—sarcoma	0.000925	0.00298	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dactinomycin—sarcoma	0.000924	0.00298	CcSEcCtD
Carfilzomib—Anorexia—Thiotepa—sarcoma	0.000906	0.00292	CcSEcCtD
Carfilzomib—Leukopenia—Mitoxantrone—sarcoma	0.0009	0.00291	CcSEcCtD
Carfilzomib—Anorexia—Dactinomycin—sarcoma	0.000899	0.0029	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—sarcoma	0.000892	0.00288	CcSEcCtD
Carfilzomib—Hypertension—Vincristine—sarcoma	0.000892	0.00288	CcSEcCtD
Carfilzomib—Cough—Mitoxantrone—sarcoma	0.000878	0.00283	CcSEcCtD
Carfilzomib—Hypertension—Mitoxantrone—sarcoma	0.000869	0.0028	CcSEcCtD
Carfilzomib—Hepatic failure—Epirubicin—sarcoma	0.000867	0.0028	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000866	0.0028	CcSEcCtD
Carfilzomib—Chills—Etoposide—sarcoma	0.000862	0.00278	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—sarcoma	0.000862	0.00278	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00086	0.00277	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—sarcoma	0.000859	0.00277	CcSEcCtD
Carfilzomib—Arthralgia—Mitoxantrone—sarcoma	0.000856	0.00276	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—sarcoma	0.000844	0.00272	CcSEcCtD
Carfilzomib—Infection—Vincristine—sarcoma	0.000838	0.0027	CcSEcCtD
Carfilzomib—ABCB1—myometrium—sarcoma	0.000837	0.00371	CbGeAlD
Carfilzomib—Decreased appetite—Thiotepa—sarcoma	0.000826	0.00267	CcSEcCtD
Carfilzomib—Thrombocytopenia—Vincristine—sarcoma	0.000825	0.00266	CcSEcCtD
Carfilzomib—Decreased appetite—Dactinomycin—sarcoma	0.00082	0.00265	CcSEcCtD
Carfilzomib—Fatigue—Thiotepa—sarcoma	0.00082	0.00265	CcSEcCtD
Carfilzomib—Infection—Mitoxantrone—sarcoma	0.000816	0.00263	CcSEcCtD
Carfilzomib—Fatigue—Dactinomycin—sarcoma	0.000814	0.00263	CcSEcCtD
Carfilzomib—Pain—Thiotepa—sarcoma	0.000813	0.00262	CcSEcCtD
Carfilzomib—Constipation—Thiotepa—sarcoma	0.000813	0.00262	CcSEcCtD
Carfilzomib—Back pain—Etoposide—sarcoma	0.000809	0.00261	CcSEcCtD
Carfilzomib—Pain—Dactinomycin—sarcoma	0.000807	0.0026	CcSEcCtD
Carfilzomib—ABCB1—embryo—sarcoma	0.000805	0.00356	CbGeAlD
Carfilzomib—Muscle spasms—Etoposide—sarcoma	0.000805	0.0026	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mitoxantrone—sarcoma	0.000804	0.00259	CcSEcCtD
Carfilzomib—Anorexia—Vincristine—sarcoma	0.000804	0.00259	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—sarcoma	0.000802	0.00259	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—sarcoma	0.000795	0.00256	CcSEcCtD
Carfilzomib—Anorexia—Mitoxantrone—sarcoma	0.000783	0.00253	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—sarcoma	0.000782	0.00252	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—sarcoma	0.000781	0.00252	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—sarcoma	0.000779	0.00251	CcSEcCtD
Carfilzomib—Anaemia—Etoposide—sarcoma	0.000773	0.0025	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Vincristine—sarcoma	0.000768	0.00248	CcSEcCtD
Carfilzomib—Insomnia—Vincristine—sarcoma	0.000763	0.00246	CcSEcCtD
Carfilzomib—ABCB1—seminal vesicle—sarcoma	0.000756	0.00335	CbGeAlD
Carfilzomib—Body temperature increased—Thiotepa—sarcoma	0.000752	0.00243	CcSEcCtD
Carfilzomib—Leukopenia—Etoposide—sarcoma	0.000749	0.00242	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000748	0.00241	CcSEcCtD
Carfilzomib—Body temperature increased—Dactinomycin—sarcoma	0.000746	0.00241	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—sarcoma	0.000741	0.00239	CcSEcCtD
Carfilzomib—Decreased appetite—Vincristine—sarcoma	0.000733	0.00237	CcSEcCtD
Carfilzomib—Dyspnoea—Mitoxantrone—sarcoma	0.000732	0.00236	CcSEcCtD
Carfilzomib—Cough—Etoposide—sarcoma	0.00073	0.00236	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—sarcoma	0.00073	0.00235	CcSEcCtD
Carfilzomib—Fatigue—Vincristine—sarcoma	0.000727	0.00235	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—sarcoma	0.000724	0.00234	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—sarcoma	0.000722	0.00233	CcSEcCtD
Carfilzomib—Pain—Vincristine—sarcoma	0.000721	0.00233	CcSEcCtD
Carfilzomib—Constipation—Vincristine—sarcoma	0.000721	0.00233	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—sarcoma	0.000721	0.00233	CcSEcCtD
Carfilzomib—ABCB1—hematopoietic system—sarcoma	0.000718	0.00318	CbGeAlD
Carfilzomib—Decreased appetite—Mitoxantrone—sarcoma	0.000714	0.0023	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—sarcoma	0.000709	0.00229	CcSEcCtD
Carfilzomib—Fatigue—Mitoxantrone—sarcoma	0.000708	0.00228	CcSEcCtD
Carfilzomib—Pain—Mitoxantrone—sarcoma	0.000702	0.00227	CcSEcCtD
Carfilzomib—Constipation—Mitoxantrone—sarcoma	0.000702	0.00227	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000701	0.00226	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—sarcoma	0.000685	0.00221	CcSEcCtD
Carfilzomib—Asthenia—Thiotepa—sarcoma	0.000682	0.0022	CcSEcCtD
Carfilzomib—Infection—Etoposide—sarcoma	0.000678	0.00219	CcSEcCtD
Carfilzomib—Asthenia—Dactinomycin—sarcoma	0.000677	0.00218	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—sarcoma	0.000675	0.00218	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—sarcoma	0.000669	0.00216	CcSEcCtD
Carfilzomib—Body temperature increased—Vincristine—sarcoma	0.000666	0.00215	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—sarcoma	0.000656	0.00212	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—sarcoma	0.000651	0.0021	CcSEcCtD
Carfilzomib—Diarrhoea—Thiotepa—sarcoma	0.00065	0.0021	CcSEcCtD
Carfilzomib—Body temperature increased—Mitoxantrone—sarcoma	0.000649	0.00209	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000649	0.00209	CcSEcCtD
Carfilzomib—Diarrhoea—Dactinomycin—sarcoma	0.000646	0.00208	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—sarcoma	0.000629	0.00203	CcSEcCtD
Carfilzomib—Dizziness—Thiotepa—sarcoma	0.000629	0.00203	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—sarcoma	0.000626	0.00202	CcSEcCtD
Carfilzomib—Dyspnoea—Etoposide—sarcoma	0.000609	0.00196	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—sarcoma	0.000607	0.00196	CcSEcCtD
Carfilzomib—Asthenia—Vincristine—sarcoma	0.000605	0.00195	CcSEcCtD
Carfilzomib—Vomiting—Thiotepa—sarcoma	0.000604	0.00195	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—sarcoma	0.000604	0.00195	CcSEcCtD
Carfilzomib—Vomiting—Dactinomycin—sarcoma	0.0006	0.00194	CcSEcCtD
Carfilzomib—Headache—Thiotepa—sarcoma	0.000596	0.00192	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—sarcoma	0.000594	0.00192	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—sarcoma	0.00059	0.0019	CcSEcCtD
Carfilzomib—Asthenia—Mitoxantrone—sarcoma	0.000589	0.0019	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—sarcoma	0.000589	0.0019	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—sarcoma	0.000588	0.0019	CcSEcCtD
Carfilzomib—Pain—Etoposide—sarcoma	0.000584	0.00188	CcSEcCtD
Carfilzomib—Constipation—Etoposide—sarcoma	0.000584	0.00188	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—sarcoma	0.000582	0.00188	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000579	0.00187	CcSEcCtD
Carfilzomib—Diarrhoea—Vincristine—sarcoma	0.000577	0.00186	CcSEcCtD
Carfilzomib—Nausea—Thiotepa—sarcoma	0.000565	0.00182	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—sarcoma	0.000562	0.00181	CcSEcCtD
Carfilzomib—Diarrhoea—Mitoxantrone—sarcoma	0.000562	0.00181	CcSEcCtD
Carfilzomib—Nausea—Dactinomycin—sarcoma	0.00056	0.00181	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—sarcoma	0.000559	0.0018	CcSEcCtD
Carfilzomib—Dizziness—Vincristine—sarcoma	0.000557	0.0018	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—sarcoma	0.000546	0.00176	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—sarcoma	0.000544	0.00176	CcSEcCtD
Carfilzomib—ABCB1—uterus—sarcoma	0.000543	0.0024	CbGeAlD
Carfilzomib—Body temperature increased—Etoposide—sarcoma	0.00054	0.00174	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—sarcoma	0.000536	0.00173	CcSEcCtD
Carfilzomib—Vomiting—Vincristine—sarcoma	0.000536	0.00173	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—sarcoma	0.000531	0.00171	CcSEcCtD
Carfilzomib—Headache—Vincristine—sarcoma	0.000528	0.0017	CcSEcCtD
Carfilzomib—Vomiting—Mitoxantrone—sarcoma	0.000522	0.00168	CcSEcCtD
Carfilzomib—Headache—Mitoxantrone—sarcoma	0.000514	0.00166	CcSEcCtD
Carfilzomib—ABCB1—lymphoid tissue—sarcoma	0.000506	0.00224	CbGeAlD
Carfilzomib—Nausea—Vincristine—sarcoma	0.000501	0.00162	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—sarcoma	0.0005	0.00161	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—sarcoma	0.000496	0.0016	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—sarcoma	0.000491	0.00159	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—sarcoma	0.00049	0.00158	CcSEcCtD
Carfilzomib—Nausea—Mitoxantrone—sarcoma	0.000488	0.00157	CcSEcCtD
Carfilzomib—Chills—Epirubicin—sarcoma	0.000483	0.00156	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—sarcoma	0.000467	0.00151	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—sarcoma	0.000463	0.00149	CcSEcCtD
Carfilzomib—ABCB1—bone marrow—sarcoma	0.000461	0.00204	CbGeAlD
Carfilzomib—Back pain—Epirubicin—sarcoma	0.000454	0.00146	CcSEcCtD
Carfilzomib—Dizziness—Etoposide—sarcoma	0.000452	0.00146	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—sarcoma	0.000451	0.00146	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—sarcoma	0.000447	0.00144	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—sarcoma	0.000434	0.0014	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—sarcoma	0.000434	0.0014	CcSEcCtD
Carfilzomib—Headache—Etoposide—sarcoma	0.000428	0.00138	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—sarcoma	0.00042	0.00135	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—sarcoma	0.00042	0.00135	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—sarcoma	0.000417	0.00135	CcSEcCtD
Carfilzomib—Cough—Epirubicin—sarcoma	0.000409	0.00132	CcSEcCtD
Carfilzomib—Nausea—Etoposide—sarcoma	0.000406	0.00131	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—sarcoma	0.000405	0.00131	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—sarcoma	0.000401	0.00129	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—sarcoma	0.000399	0.00129	CcSEcCtD
Carfilzomib—ABCB1—testis—sarcoma	0.000394	0.00174	CbGeAlD
Carfilzomib—Leukopenia—Doxorubicin—sarcoma	0.000388	0.00125	CcSEcCtD
Carfilzomib—Infection—Epirubicin—sarcoma	0.00038	0.00123	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—sarcoma	0.000379	0.00122	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—sarcoma	0.000375	0.00121	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—sarcoma	0.000375	0.00121	CcSEcCtD
Carfilzomib—ABCB1—liver—sarcoma	0.000372	0.00165	CbGeAlD
Carfilzomib—Arthralgia—Doxorubicin—sarcoma	0.000369	0.00119	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—sarcoma	0.000365	0.00118	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—sarcoma	0.000352	0.00114	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000349	0.00113	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—sarcoma	0.000347	0.00112	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—sarcoma	0.000346	0.00112	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—sarcoma	0.000341	0.0011	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—sarcoma	0.000338	0.00109	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—sarcoma	0.000333	0.00107	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—sarcoma	0.00033	0.00107	CcSEcCtD
Carfilzomib—Pain—Epirubicin—sarcoma	0.000327	0.00106	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—sarcoma	0.000327	0.00106	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000323	0.00104	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—sarcoma	0.00032	0.00103	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—sarcoma	0.000316	0.00102	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—sarcoma	0.000308	0.000994	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—sarcoma	0.000305	0.000986	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—sarcoma	0.000303	0.000978	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—sarcoma	0.000303	0.000978	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—sarcoma	0.000303	0.000977	CcSEcCtD
Carfilzomib—ABCB1—lymph node—sarcoma	0.000285	0.00126	CbGeAlD
Carfilzomib—Body temperature increased—Doxorubicin—sarcoma	0.00028	0.000904	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—sarcoma	0.000275	0.000886	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—sarcoma	0.000262	0.000845	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—sarcoma	0.000254	0.00082	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—sarcoma	0.000253	0.000817	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—sarcoma	0.000243	0.000785	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—sarcoma	0.000242	0.000782	CcSEcCtD
Carfilzomib—Headache—Epirubicin—sarcoma	0.00024	0.000774	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—sarcoma	0.000234	0.000756	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—sarcoma	0.000227	0.000734	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—sarcoma	0.000225	0.000727	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—sarcoma	0.000222	0.000716	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—sarcoma	0.00021	0.000679	CcSEcCtD
Carfilzomib—PSMB9—Immune System—IL2—sarcoma	8.66e-05	0.000278	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KIT—sarcoma	8.66e-05	0.000278	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KIT—sarcoma	8.66e-05	0.000278	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KIT—sarcoma	8.66e-05	0.000278	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KDR—sarcoma	8.64e-05	0.000277	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KIT—sarcoma	8.53e-05	0.000274	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—JUN—sarcoma	8.47e-05	0.000272	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—JUN—sarcoma	8.43e-05	0.00027	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CTNNB1—sarcoma	8.41e-05	0.00027	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CTNNB1—sarcoma	8.36e-05	0.000268	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF1R—sarcoma	8.36e-05	0.000268	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF1R—sarcoma	8.36e-05	0.000268	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF1R—sarcoma	8.36e-05	0.000268	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—EGFR—sarcoma	8.32e-05	0.000267	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—EGFR—sarcoma	8.32e-05	0.000267	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—EGFR—sarcoma	8.32e-05	0.000267	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF1R—sarcoma	8.24e-05	0.000264	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CREB1—sarcoma	8.24e-05	0.000264	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CREB1—sarcoma	8.24e-05	0.000264	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CREB1—sarcoma	8.24e-05	0.000264	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—EGFR—sarcoma	8.2e-05	0.000263	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CREB1—sarcoma	8.12e-05	0.000261	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KIT—sarcoma	8e-05	0.000257	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KIT—sarcoma	7.96e-05	0.000255	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—FOXO1—sarcoma	7.96e-05	0.000255	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—FOXO1—sarcoma	7.96e-05	0.000255	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—FOXO1—sarcoma	7.96e-05	0.000255	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PDGFRB—sarcoma	7.94e-05	0.000255	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PDGFRB—sarcoma	7.94e-05	0.000255	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PDGFRB—sarcoma	7.94e-05	0.000255	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	7.87e-05	0.000252	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KRAS—sarcoma	7.86e-05	0.000252	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KRAS—sarcoma	7.86e-05	0.000252	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KRAS—sarcoma	7.86e-05	0.000252	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	7.85e-05	0.000252	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FOXO1—sarcoma	7.84e-05	0.000252	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PDGFRB—sarcoma	7.83e-05	0.000251	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PDGFRA—sarcoma	7.82e-05	0.000251	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PDGFRA—sarcoma	7.82e-05	0.000251	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PDGFRA—sarcoma	7.82e-05	0.000251	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	7.79e-05	0.00025	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—CTNNB1—sarcoma	7.76e-05	0.000249	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—KRAS—sarcoma	7.75e-05	0.000248	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CTNNB1—sarcoma	7.72e-05	0.000248	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PDGFRA—sarcoma	7.71e-05	0.000247	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—sarcoma	7.63e-05	0.000245	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—sarcoma	7.63e-05	0.000245	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—sarcoma	7.63e-05	0.000245	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CREB1—sarcoma	7.61e-05	0.000244	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—SRC—sarcoma	7.6e-05	0.000244	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CREB1—sarcoma	7.58e-05	0.000243	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—SRC—sarcoma	7.56e-05	0.000242	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—sarcoma	7.52e-05	0.000241	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MDM2—sarcoma	7.38e-05	0.000237	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MDM2—sarcoma	7.38e-05	0.000237	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MDM2—sarcoma	7.38e-05	0.000237	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—NRAS—sarcoma	7.31e-05	0.000234	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MDM2—sarcoma	7.28e-05	0.000233	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—NRAS—sarcoma	7.27e-05	0.000233	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	7.04e-05	0.000226	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—SRC—sarcoma	7.01e-05	0.000225	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—SRC—sarcoma	6.98e-05	0.000224	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	6.86e-05	0.00022	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MDM2—sarcoma	6.82e-05	0.000219	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MDM2—sarcoma	6.82e-05	0.000219	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MDM2—sarcoma	6.82e-05	0.000219	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—MYC—sarcoma	6.77e-05	0.000217	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—NRAS—sarcoma	6.75e-05	0.000216	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MYC—sarcoma	6.74e-05	0.000216	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MDM2—sarcoma	6.72e-05	0.000216	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—NRAS—sarcoma	6.72e-05	0.000215	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HRAS—sarcoma	6.68e-05	0.000214	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HRAS—sarcoma	6.68e-05	0.000214	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HRAS—sarcoma	6.68e-05	0.000214	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—EGFR—sarcoma	6.66e-05	0.000214	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—EGFR—sarcoma	6.63e-05	0.000213	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL2—sarcoma	6.6e-05	0.000212	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL2—sarcoma	6.6e-05	0.000212	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL2—sarcoma	6.6e-05	0.000212	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HRAS—sarcoma	6.59e-05	0.000211	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KDR—sarcoma	6.58e-05	0.000211	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KDR—sarcoma	6.58e-05	0.000211	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KDR—sarcoma	6.58e-05	0.000211	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL2—sarcoma	6.51e-05	0.000209	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KDR—sarcoma	6.49e-05	0.000208	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—JUN—sarcoma	6.42e-05	0.000206	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—JUN—sarcoma	6.42e-05	0.000206	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—JUN—sarcoma	6.42e-05	0.000206	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CTNNB1—sarcoma	6.37e-05	0.000204	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CTNNB1—sarcoma	6.37e-05	0.000204	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CTNNB1—sarcoma	6.37e-05	0.000204	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—JUN—sarcoma	6.33e-05	0.000203	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	6.31e-05	0.000202	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MDM2—sarcoma	6.3e-05	0.000202	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KRAS—sarcoma	6.29e-05	0.000202	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MYC—sarcoma	6.29e-05	0.000202	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CTNNB1—sarcoma	6.28e-05	0.000201	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MDM2—sarcoma	6.27e-05	0.000201	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KRAS—sarcoma	6.26e-05	0.000201	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MYC—sarcoma	6.26e-05	0.000201	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	6.17e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—sarcoma	6.15e-05	0.000197	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—sarcoma	6.12e-05	0.000196	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KIT—sarcoma	6.06e-05	0.000194	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KIT—sarcoma	6.06e-05	0.000194	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KIT—sarcoma	6.06e-05	0.000194	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KIT—sarcoma	5.98e-05	0.000192	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CTNNB1—sarcoma	5.88e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CTNNB1—sarcoma	5.88e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CTNNB1—sarcoma	5.88e-05	0.000189	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	5.83e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KRAS—sarcoma	5.81e-05	0.000186	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CTNNB1—sarcoma	5.8e-05	0.000186	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KRAS—sarcoma	5.78e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CREB1—sarcoma	5.77e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CREB1—sarcoma	5.77e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CREB1—sarcoma	5.77e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—SRC—sarcoma	5.76e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—SRC—sarcoma	5.76e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—SRC—sarcoma	5.76e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CREB1—sarcoma	5.69e-05	0.000182	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—SRC—sarcoma	5.68e-05	0.000182	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2—sarcoma	5.63e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2—sarcoma	5.6e-05	0.00018	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NRAS—sarcoma	5.54e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NRAS—sarcoma	5.54e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NRAS—sarcoma	5.54e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—sarcoma	5.49e-05	0.000176	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—JUN—sarcoma	5.48e-05	0.000176	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—sarcoma	5.46e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NRAS—sarcoma	5.46e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—JUN—sarcoma	5.45e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CTNNB1—sarcoma	5.43e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CTNNB1—sarcoma	5.41e-05	0.000173	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—sarcoma	5.35e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—sarcoma	5.32e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—SRC—sarcoma	5.32e-05	0.00017	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—SRC—sarcoma	5.32e-05	0.00017	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—SRC—sarcoma	5.32e-05	0.00017	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—SRC—sarcoma	5.24e-05	0.000168	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	5.18e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—sarcoma	5.13e-05	0.000165	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—sarcoma	5.13e-05	0.000165	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—sarcoma	5.13e-05	0.000165	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NRAS—sarcoma	5.11e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NRAS—sarcoma	5.11e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NRAS—sarcoma	5.11e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—sarcoma	5.06e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—sarcoma	5.05e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—sarcoma	5.05e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—sarcoma	5.05e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—sarcoma	5.04e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—sarcoma	4.98e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—sarcoma	4.94e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—sarcoma	4.91e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SRC—sarcoma	4.91e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SRC—sarcoma	4.89e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—sarcoma	4.78e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MDM2—sarcoma	4.77e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MDM2—sarcoma	4.77e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MDM2—sarcoma	4.77e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—sarcoma	4.77e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—sarcoma	4.77e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—sarcoma	4.77e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—sarcoma	4.76e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—sarcoma	4.76e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—sarcoma	4.76e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—sarcoma	4.76e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—sarcoma	4.73e-05	0.000152	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MDM2—sarcoma	4.71e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—sarcoma	4.7e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—sarcoma	4.7e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—sarcoma	4.7e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—sarcoma	4.66e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—sarcoma	4.66e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—sarcoma	4.66e-05	0.000149	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO2—sarcoma	4.65e-05	0.000149	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HBA1—sarcoma	4.62e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—sarcoma	4.59e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—sarcoma	4.4e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—sarcoma	4.4e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—sarcoma	4.4e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—sarcoma	4.4e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—sarcoma	4.38e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—sarcoma	4.34e-05	0.000139	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—sarcoma	4.31e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—sarcoma	4.28e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—sarcoma	4.27e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—sarcoma	4.27e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—sarcoma	4.27e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—sarcoma	4.21e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—sarcoma	4.16e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—sarcoma	4.16e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—sarcoma	4.16e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JUN—sarcoma	4.15e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JUN—sarcoma	4.15e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JUN—sarcoma	4.15e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—sarcoma	4.12e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—sarcoma	4.12e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—sarcoma	4.12e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—sarcoma	4.1e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JUN—sarcoma	4.09e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—sarcoma	4.07e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—sarcoma	4.06e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—sarcoma	4.05e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—sarcoma	4.05e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—sarcoma	4.05e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—sarcoma	4.05e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—sarcoma	4e-05	0.000128	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PLCG1—sarcoma	3.95e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—sarcoma	3.74e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—sarcoma	3.74e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—sarcoma	3.74e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—sarcoma	3.72e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—sarcoma	3.72e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—sarcoma	3.72e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—sarcoma	3.69e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—sarcoma	3.67e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—sarcoma	3.63e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—sarcoma	3.63e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—sarcoma	3.63e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—sarcoma	3.61e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—sarcoma	3.6e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—sarcoma	3.58e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—sarcoma	3.58e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—sarcoma	3.58e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—sarcoma	3.57e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—sarcoma	3.53e-05	0.000113	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—sarcoma	3.46e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—sarcoma	3.44e-05	0.00011	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—sarcoma	3.34e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—sarcoma	3.34e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—sarcoma	3.34e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—sarcoma	3.29e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—sarcoma	3.26e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—sarcoma	3.26e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—sarcoma	3.26e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—sarcoma	3.22e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—sarcoma	3.08e-05	9.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—sarcoma	3.08e-05	9.88e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—sarcoma	3.08e-05	9.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—sarcoma	3.04e-05	9.74e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—sarcoma	2.74e-05	8.78e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—sarcoma	2.74e-05	8.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—sarcoma	2.74e-05	8.78e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—sarcoma	2.7e-05	8.66e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—sarcoma	2.62e-05	8.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—sarcoma	2.62e-05	8.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—sarcoma	2.62e-05	8.4e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—sarcoma	2.58e-05	8.28e-05	CbGpPWpGaD
